}}</ref> and progressed as far as Phase II [[clinical trials]] for [[Parkinson's disease]],<ref>The Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. ''Neurology''. 2006;66:408-410. {{doi|10.1212/01.wnl.0000196466.99381.5c}}</ref> where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.
